35 might factor in 113 and ponatinib but doesn't value the other products undoubtably currently in development. I would hate to see the company purchased for such a paltry amount given the potential for a much higher valuation within a relatively short time frame of five to ten years, if, as I hope and suspect, the research time has actually achieved a paradigm shift in the ability to produce successful drugs.
That would be truely lovely. I am a little surprised that we've had very little to no merger speculation or known interest. Clearly there is some value here that Big Pharma would like to have. I do think its only a matter of time before someone makes an offer. However, I make it a point not to invest on the hopes of merger speculation, but I wouldn't mind benefiting from it.